LEROCHOL
Launchlerodalcibep-liga
BLAINJECTIONINJECTABLE
Approved
Dec 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
2/8 — Basic
LEROCHOL (lerodalcibep-liga) is lerodalcibep-liga is a recombinant fusion protein that binds pcsk9 with picomolar affinity. First approved in 2025.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LEROCHOL (lerodalcibep-liga) is a recombinant fusion protein that inhibits PCSK9 binding to LDLR, increasing hepatic LDL receptor availability and lowering LDL-C levels. It is indicated for hypercholesterolemia, familial hypercholesterolemia, and cardiovascular disease prevention. Administered via injection, it represents a next-generation approach to lipid management beyond statins and other oral agents.
Launch
Recent approval positions LEROCHOL in a growth phase; commercial infrastructure and field teams will expand significantly during launch ramp.
Mechanism of Action
Lerodalcibep-liga is a recombinant fusion protein that binds PCSK9 with picomolar affinity. PCSK9 binds to low-density lipoprotein receptor (LDLR) on the surface of hepatocytes to promote LDLR degradation within the liver. By inhibiting the binding of PCSK9 to LDLR, lerodalcibep-liga increases the…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LEROCHOL's launch phase presents high-impact career opportunities in brand building, managed care navigation, and field execution in the competitive lipid-management space. The injectable biologic format and specialist positioning (cardiology, endocrinology) create focused roles requiring deep disease and competitive knowledge.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.